Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer

Fig. 5

CDKL1 overexpression downregulates the expression of PD-L1 through YBX1. (A) The mRNA level of PD-L1 was assessed in A549 and H1299 cells using qPCR (*** P < 0.001). (B) The protein level of PD-L1 in A549 and H1299 cells overexpressing CDKL1 or transfected with si-CDKL1 was determined using western blotting. (C) H1299 cells were transfected with SFB-CDKL1, and the expression of PD-L1 on the surface of living cells was determined using flow cytometry (* P < 0.05). (D) SiRNA was transfected into H1299 cells to silence CDKL1, and the expression of PD-L1 on the surface of living cells was determined using flow cytometry (*** P < 0.001). (E) The mRNA and protein levels of PD-L1 were assessed using qPCR after CDKL1 was overexpressed in Lewis cells. (F) The expression of PD-L1 on the cell surface of Lewis cells overexpressing CDKL1 was examined using flow cytometry (*** P < 0.001). (G) The protein and mRNA expression levels of PD-L1 were determined in A549 cells (n.s. P > 0.05, *** P < 0.001)

Back to article page